Depending on the drug, it may also lower cardiovascular risk or the likelihood of kidney complications in those with type 2 diabetes, ease heart failure symptoms, reduce liver fat, improve metabolic dysfunction, and lessen the severity of sleep apnea
The cost-effectiveness of oral semaglutide in the Health Canadaapproved population is uncertain due to the limitations identified with the modelling approach undertaken by the sponsor and the difference in the modelled population and the Health Canadaapproved population
Enrolled over 5,800 participants
Patient descriptions from TRIUMPH-4: "Tingling in my hands and feet, like they fell asleep" "Strange sensation when I touch my skin, not painful but unusual" "Numbness in fingertips, comes and goes" "Pins and needles feeling, especially in the morning" NOT described: Severe pain Progressive worsening (stays stable or improves) Interference with daily activities (most continued trial) Why Is This Unique to Retatrutide